|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Gain-of-function pathogenic variants of the Erb-B2 receptor tyrosine kinase 3 (ERBB3) gene contribute to the occurrence and development of a variety of human carcinomas through activation of phosphatidylinositol 3-kinase (PI3K)/AKT and extracellular signal-regulated kinase (ERK) signaling.
|
31752936 |
2019 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Altogether, we examined HER3 in ovarian high-grade serous (HGSC, n = 320), low-grade serous (LGSC, n = 55), endometrioid (EC, n = 33), and clear cell (CCC, n = 48) carcinomas using immunohistochemistry (IHC) and quantitative real-time reverse transcription PCR (qRT-PCR).
|
27913862 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized, glycoengineered, anti-HER3 monoclonal antibody (mAb), in combination with the EGFR-blocking agents erlotinib or cetuximab in patients with advanced HER3-positive carcinomas.<b>Experimental Design:</b> The study included two parts: dose escalation and dose extension phases with lumretuzumab in combination with either cetuximab or erlotinib, respectively.
|
28600476 |
2017 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we analyzed the immunoexpression of EGFR, HER2 (EGFR2) and HER3 (EGFR3) in 41 cases of serous borderline ovarian tumors and carcinomas, in relation to the degree of differentiation and tumor stage.
|
29556616 |
2017 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
HER2 or ERBB3 alterations are predictive of afatinib response in refractory urothelial carcinomas.
|
27080337 |
2016 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
|
26296355 |
2015 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The sensitivity to KF in a panel of human tumor cell lines derived from breast (SKBR3, BT474, and MCF7), vulval (A431), non-small-cell lung (H460, A549, SW1573, and H292), and hepatic (Skhep1, HepG2, and Hep3B) carcinomas positively correlated with ErbB3 (HER3) protein levels.
|
15908515 |
2005 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In this study, we examined Her-1, Her-2, and Her- 3 protein expression as well as the frequency of Her-2 amplification in a series of 103 high-grade, advanced-stage (FIGO stage III or IV) ovarian surface epithelial carcinomas.
|
15782071 |
2005 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The latter is suggested by the frequent overexpression of HER-2, EGFR, and HER-3 in some human carcinomas, primarily breast and squamous cancer.
|
15254961 |
2004 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together, activation of ErbB3 pathway may contribute to the development of dedifferentiated carcinomas.
|
12618754 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
To determine the influence of receptor tyrosine kinases, which are both expressed in pulmonary carcinomas and in human skin, we performed expression studies on epidermal growth factor receptor (EGFR), HER2, HER3 in a skin sample of tripe palms obtained from a patient with non-small-cell lung cancer with lymph node involvement.
|
10640836 |
1999 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
All the normal control oral mucosa showed the same pattern of staining for c-erbB-2, c-erbB-3 and c-erbB-4 found in the epithelium located near the carcinomas.
|
9494565 |
1998 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It was found that the overexpression of c-erbB3 protein was observed in 67% (6/9) of comedo DCIS, 52% (44/84) of invasive ductal carcinomas, 71% (5/7) of carcinomas containing both the in situ and invasive lesions and 25% (1/4) of invasive lobular carcinomas.
|
9823984 |
1998 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The erbB2 and erbB3 were more strongly expressed than the epidermal growth factor receptor in the primary carcinomas.
|
7847801 |
1995 |